En español
NIDA

Menu

Home » Funding » Funding Opportunities » Small Business Funding » Step Three - SBIR/STTR Funding Areas

Step Three - SBIR/STTR Funding Areas

Check out our diverse array of NIDA's SBIR/STTR funding interests.

For GENERAL areas of interest, see our table below.

If you do not see your area of interest, please contact us, we still might be interested!

If you have any questions, please direct them to the SBIR contacts listed in the table below or Dr. Elena Koustova.

General Area Potential Topics of SBIR Interest Program Contact
Drug Development
Drug Development
  • Chemistry / pharmaceutical drug development
  • Formulation and/or enhanced delivery of new drugs
  • Preclinical drug development
  • Clinical drug development
  • Development of a clinical diagnostic test/device
  • Development of biomarkers related to treatment outcomes
  • Creation of a data repository / software tool for addiction-related clinical research data
 Dr. Kristopher Bough
301-443-9800
Science Policy & Communication
Science Policy & Communication
  • Development of innovative science education materials for K-12 students, the general public, health care practitioners, museums, media experts, and others
 Dr. Elena Koustova
301-496-8768
Epidemiology, Education, and Prevention
Epidemiology, Education, and Prevention
  • Prescription drug prevention and services studies
  • Dissemination research, focused on factors that promote faster uptake of effective prevention services
  • Implementation Research, focused on alternative delivery mechanisms for school curricula, family programs, and community interventions
  • Studies of addiction recovery and offender reintegration systems, focused on ways to enhance treatment delivery to higher risk recidivists
  • Enhanced approaches to working with medical care providers to maximize the delivery of effective treatment services
  • Development and study of assessment innovative technological tools of addiction risk, and including ecological momentary assessment across a wide variety of settings (home, workplace, neighborhood)
 Dr. Augie Diana
301-443-1942
Clinical & Behavioral Neuroscience Clinical & Behavioral Neuroscience
  • Complementary and alternative therapies for drug abuse treatment
  • Virtual reality applications for treating drug abuse
  • Web- and mobile-phone based tools for treating drug dependence
  • Development of sensitive web- or mobile-based behavioral programs that enhance compliance, complement pharmacological treatments, and/or improve treatment access for underserved populations
  • Products that enhance treatment effectiveness to community practitioners
  • Develop interactive database systems on human subjects issues for use by drug abuse researchers studying school-age children and adolescents drug use
  • Develop new neuroimaging tools to assess structural and functional status of the brains of adolescents exposed to drugs of abuse
 Dr. CeCe Spitznas
301-402-1488
Basic Neuroscience
Basic Neuroscience
  • Development of innovative technologies, methods or tools for the molecular analysis of the brain such as:
    • Innovative in vitro, in situ, or in vivo tools for the molecular analysis of the central nervous system
    • Development of pre-clinical models for addiction
    • Novel analytical technologies that enhance the understanding of basic mechanisms of drug action and improve drug testing
  • The application of existing and emerging technologies for addiction research to:
    • Development of data-driven models of signal transduction networks that can be applied to gain predictive insight into basic biological tenets underlying drug addiction
    • General products with the potential to aid in the basic understanding of behavioral, neurobiological, cellular, molecular, chemical, and genetics processes of addiction (among others) ?products that minimize drug seeking, compulsive behavior, and/or addictive processes in particular are encouraged
 Dr. Elena Koustova
301-496-8768
Collaborative Clinical Trials Network
  • Projects that would simplify, automate, standardize, or reduce the cost of administration of clinical research instruments used in CTN trials
  • Projects that would reduce error rates in completing assessment or clinical instruments and in transmitting data to data management entities
  • Projects to develop instruments that measure factors relevant and important to the conduct of addictions research, such as: the extent of craving and/or of withdrawal, the risk of addiction to a particular substance, the therapeutic alliance between patient and therapist, perceived satisfaction with health care, probabilities of a pain management patient developing dependence/abuse on pain medications, and the probability of successfully completing detoxification
  • Projects to develop instruments that measure and predict HIV risk behaviors
  • Projects that develop and evaluate innovative diagnostic drug screening tests for drug abuse, such as oral swabs
  • Projects that develop and evaluate the use of gene chip technology for drug abuse risk factors
 Ms. Quandra Scudder
301-594-0394

    Attention

    Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at

    USA.gov

    Looking for Treatment?

    Use the SAMHSA Treatment Locator or 1-800-662-HELP.

    Helpline open during government shutdown

    Search for Funding

    Featured Publication

    Mentoring, A Guide for Drug Abuse Researchers publication cover

    Mentoring: A Guide for Drug Abuse Researchers

    Discusses the importance of quality mentorship in drug abuse research and offers suggestions for creating a successful mentor and mentee relationship.

    Read more

    NIDA's Publication Series